Table 1 Patient characteristics at start of treatment with etanercept

Female gender

1146 (66.5%)

224 (66.3%)

32 (59.3%)

Age, years, mean (SD)

13.4 (3.5)

15.9 (4.3)

17.1 (5.1)

 < 10 years

231 (13.4%)

17 (5.0%)

1 (1.9%)

 10 to < 15 years

732 (42.5%)

97 (28.7%)

16 (29.6%)

 > 15 years

761 (44.1%)

224 (66.3%)

37 (68.5%)

 Systemic JIA

111 (6.4%)

22 (6.5%)

4 (7.4%)

 Polyarticular arthritis, RF-negative

487 (28.3%)

100 (29.6%)

21 (38.9%)

 Polyarticular arthritis RF-positive

176 (10.2%)

25 (7.4%)

4 (7.4%)

 Persistent oligoarthritis

73 (4.2%)

14 (4.1%)

1 (1.9%)

 Extended oligoarthritis

307 (17.8%)

69 (20.4%)

9 (16.7%)

 Enthesitis-related arthritis

359 (20.8%)

65 (19.2%)

9 (16.7%)

 Psoriatic arthritis

148 (8.6%)

33 (9.8%)

2 (3.7%)

 Undifferentiated arthritis

63 (3.7%)

10 (3.0%)

4 (7.4%)

 ANA positive

723 (43.9%)

134 (39.8%)

19 (35.2%)

 HLA-B27 positive

472 (30.3%)

103 (30.6%)

14 (25.9%)

Physician’s global assessment, VAS score, mean (SD)

5.3 (2.7)

3.2 (2.8)

2.9 (2.5)

 CRP, mg/dl, mean (SD)

19.5 (36.1)

12.5 (27.1)

10.5 (17.3)

 ESR, mm/1 h, mean (SD)

24.6 (23.7)

19.2 (19.2)

15.8 (15.3)

 Number of joints with arthritis, mean (SD)

7.2 (8.7)

3.7 (7.6)

2.8 (3.8)

 Number of LOM joints, mean (SD)

8.0 (9.8)

4.9 (9.4)

3.5 (3.9)

 Number of swollen joints, mean (SD)

5.7 (7.9)

2.6 (6.5)

2.0 (2.9)

 Number of painful joints, mean (SD)

7.2 (9.1)

3.8 (7.8)

3.3 (4.4)

 cJADAS-10, mean (SD)

15.1 (6.8)

8.4 (7.0)

7.8 (6.8)

 CHAQ total score, mean (SD)

0.7 (0.6)

0.4 (0.6)

0.3 (0.4)

Patient-reported overall well-being, VAS score, mean (SD)

4.7 (2.8)

3.0 (2.7)

2.5 (2.6)

Patient-reported pain, VAS score, mean (SD)

4.2 (2.8)

3.1 (2.8)

2.7 (2.7)